Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25031838 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Amber R Prebble und 6 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO 80523, USA. Hauptthemen laut MEDLINE: Tyrosine Kinase Inhibitors, Indoles. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Department of Environmental and Radiological Health Sciences, Colorado State University.
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA.
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
ORCID-Profile: Amber R Prebble, Mary-Keara Boss
Förderung
- NIH HHS
- Department of Environmental and Radiological Health Sciences, Colorado State University
Zitieren
APA
Prebble, A. R., Latka, B., Burdekin, B., Leary, D., Harris, M., Regan, D., & Boss, M. K. (2024). Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031838
Vancouver
Prebble AR, Latka B, Burdekin B, Leary D, Harris M, Regan D, et al. Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031838
BibTeX
@article{Prebble2024,
author = {Prebble, Amber R and Latka, Bailey and Burdekin, Braden and Leary, Del and Harris, Mac and Regan, Daniel and Boss, Mary-Keara},
title = {Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25031838}
}
EUVIMED